Dupixent carries a list price of roughly $36,000 to $40,000 per year, putting it among the more expensive prescription drugs on the market. That price reflects a combination of factors: it’s a biologic drug that’s costly to manufacture, it holds strong patent protection with no biosimilar competition, and it treats a growing list of conditions that keep demand high.
Biologics Cost Far More to Make Than Pills
Dupixent is a monoclonal antibody, a type of drug grown inside living cells rather than assembled through chemical reactions like a traditional pill. This distinction matters enormously for cost. Manufacturing a monoclonal antibody requires specialized facilities where genetically engineered cells are cultured in large bioreactors under tightly controlled conditions. The protein molecules these cells produce are then purified through multiple steps to ensure consistency and safety. Every batch must be tested extensively because even small variations in living-cell production can change how the drug works in the body.
Traditional small-molecule drugs, by contrast, are synthesized through relatively straightforward chemical processes that can be scaled up cheaply. A generic version of a pill can often be produced for pennies per dose. Biologics don’t offer that same economy. The infrastructure, quality control, and expertise required to produce therapeutic proteins at scale represent a fundamentally higher cost floor, and that cost gets passed along in the price.
What Dupixent Does That Older Drugs Can’t
Dupixent works by blocking two immune signaling molecules, IL-4 and IL-13, that drive a specific type of inflammation involved in conditions like eczema, asthma, and nasal polyps. It does this by binding with extremely high precision to a shared receptor on cells, essentially shutting down the inflammatory cascade at its source. This targeted approach is a key part of the pricing story: Dupixent doesn’t broadly suppress the immune system the way older treatments like oral steroids or cyclosporine do. That precision means fewer serious side effects and makes it suitable for long-term use, sometimes indefinitely.
For patients with moderate-to-severe eczema who’ve failed topical treatments, or people with hard-to-control asthma, Dupixent often works when nothing else has. That therapeutic value gives the manufacturers, Regeneron and Sanofi, significant leverage in pricing negotiations with insurers. When a drug is the only effective option for a large group of patients, payers have limited ability to push back on cost.
Six FDA-Approved Uses and Growing
Dupixent is now approved for six separate conditions: moderate-to-severe atopic dermatitis (eczema) in patients as young as 6 months, moderate-to-severe asthma with an eosinophilic component, chronic sinus disease with nasal polyps, eosinophilic esophagitis, prurigo nodularis (a chronic skin condition causing intensely itchy nodules), and most recently, chronic obstructive pulmonary disease (COPD) with eosinophilic inflammation.
Each new approval expands the pool of potential patients substantially. COPD alone affects millions of adults, and the eosinophilic subtype represents a significant portion of that population. This breadth of use is unusual for a biologic and creates enormous revenue potential. It also means Regeneron and Sanofi can spread their development costs across multiple markets while maintaining a single high price point. The drug generated over $13 billion in global sales in 2024, making it one of the best-selling drugs in the world.
Patent Protection Blocks Cheaper Alternatives
Dupixent is shielded by a web of patents that extend well into the 2030s. The core composition-of-matter patent in the U.S. runs through October 2027, but additional patents covering the drug’s formulation and specific treatment methods stretch as far as July 2034. In Europe, supplementary protection extends coverage through late 2032.
Beyond patents, biologics receive 12 years of regulatory exclusivity in the United States under federal law. This means the FDA cannot approve a biosimilar (the biologic equivalent of a generic) until 12 years after Dupixent’s original approval, even if a competitor manages to develop one. Dupixent was first approved in March 2017, so this exclusivity window runs through 2029 at the earliest. And even after that window closes, the complexity of manufacturing a monoclonal antibody makes biosimilar development slower and more expensive than copying a traditional pill. A biosimilar manufacturer has to prove its version is highly similar to the original in structure, function, and clinical effect, a process that can take years and cost hundreds of millions of dollars.
The practical result: there is no cheaper alternative to Dupixent available today, and there likely won’t be one for several more years.
Limited Competition Keeps Prices High
While other biologics exist in overlapping treatment areas, none directly replicate what Dupixent does. In asthma, competing biologics like omalizumab, mepolizumab, and benralizumab each target different parts of the immune response and are priced in a similar range. They aren’t interchangeable with Dupixent, so they don’t create the kind of head-to-head price competition that drives costs down.
In eczema, tralokinumab (sold as Adbry) is the closest biologic competitor, but it targets only IL-13 rather than both IL-4 and IL-13, and its clinical track record is shorter. Newer entrants are trying to compete on price, but Dupixent’s combination of long-term efficacy data, broad label coverage across six conditions, and physician familiarity gives it a strong market position. Without meaningful biosimilar pressure or a direct equivalent from a competitor, there’s little incentive for the manufacturers to lower the price.
R&D Costs Built Into the Price
Developing a monoclonal antibody from discovery through FDA approval is extraordinarily expensive. The clinical trial program for Dupixent spanned thousands of patients across multiple conditions, each requiring its own set of large, randomized trials. Regeneron and Sanofi continued investing in additional trials for each new indication after the initial approval, a process that has been ongoing for nearly a decade. These costs are real, though it’s worth noting that the drug’s current sales volume has long since recouped the initial investment. At this point, the price reflects what the market will bear as much as what the drug cost to develop.
What Patients Actually Pay
The list price and what you pay out of pocket can be very different numbers. Most patients with commercial insurance don’t pay the full cost because insurers negotiate rebates with the manufacturer. Regeneron also offers a copay assistance program called MyWay for patients with commercial insurance, including federal and state employee plans and marketplace coverage. If you’re eligible, this card can reduce your copay significantly, sometimes to as little as $0 per month.
Patients on Medicare or Medicaid aren’t eligible for manufacturer copay cards, which can make out-of-pocket costs much harder to manage. Some patients in this situation qualify for separate patient assistance programs that provide the drug at no cost, but eligibility depends on income and other factors. If you’re struggling with the cost, your prescriber’s office or a specialty pharmacy can typically help you navigate the available options for your specific insurance situation.